Paul Cataford

Chairman of the Board
Mr. Cataford served as the Interim President & CEO of Titan Medical from December 2021 to June 2022. Prior to this role Paul was the CEO and co-founder of Zephyr Sleep Technologies Inc., a private medical device company specializing in the treatment and diagnoses of sleep-disordered breathing.
In his over 10 years at Zephyr, Mr. Cataford was able to grow the team to over 65 people, clear class II medical devices through both 510 (k) and De Novo FDA approval paths and build a 13485: 2016 certified manufacturing facility.  Zephyr successfully closed on two joint ventures with established dental technology companies raising over $20 million from a combination of strategic and private investors.  He brings significant high technology and medical device company experience and is a key contributor to strategy, M&A, corporate finance, governance, team building and empowerment and scale. Over the last 25 years, Mr. Cataford has also served as independent corporate director on a number of TSX, TSXV and NASDAQ company boards including: Sierra Wireless, Inc., Trakopolis IoT Corp., SemiBioSys Genetics Inc., and AGJunction Inc. Mr. Cataford has a Bachelor of Science degree in Mechanical Engineering from Queen’s University, an MBA specializing in Finance and International Strategy from Schulich School of Business at York University, and is a graduate of the Institute of Corporate Directors – Directors College, Rotman School of Business at the University of Toronto. 

Anthony J. Giovinazzo

Director, Governance/Nominating Committee Chair
As Governance/Nominating Committee Chair on Titan Medical’s board of directors, Mr. Giovinazzo drives continuous improvement of the Company’s governance practices. Mr. Giovinazzo is a director and executive chairman on the board of Sublimity Therapeutics, a private late clinical stage biopharmaceutical company addressing gastrointestinal and autoimmune diseases...

He is a co-inventor of the recent FDA approved drug Kynmobi, developed by Cynapsus Therapeutics Inc. (Nasdaq: CYNA) where Mr. Giovinazzo was also CEO and a director until Cynapsus was acquired in an industry leading all-cash transaction with Sunovion Pharmaceuticals Inc. for CAD $841 million. In 2017, Mr. Giovinazzo was chosen as the inaugural recipient of the Bloom Burton Award. Mr. Giovinazzo has a Chartered Director (C.Dir.) and Audit Committee Certification (ACC) from The Directors College and the DeGroote School of Business at McMaster University. He received a Bachelor of Arts degree in Economics and Accounting from McMaster University and an MBA from IMD Geneva, Switzerland.

Heather Knight

Independent Director

Heather Knight is an Independent Director of Titan Medical Inc. Ms. Knight is a sales and marketing executive with nearly 25 years of proven healthcare commercial experience. She currently serves as General Manager of U.S. Hospital Products at Baxter Healthcare where she is responsible for U.S. commercialization including sales, national accounts, marketing, commercial operations and business integration.

Ms. Knight previously served as Global President of Sofradim/France and Vice President and General Manager for Surgical Innovations, MITG at Medtronic where she led all portfolio, strategy and growth initiatives for the global business, including commercialization in all regions across the globe. Ms. Knight holds a Bachelor of Science in Biological Sciences from the State University of New York and completed the Executive Sales Strategy and Management program at the University of Chicago, Booth School of Management. She is presently enrolled in the Harvard Business School Advanced Management Executive Program.

Cathy Steiner

Independent Director & Audit Committee Chair

Ms. Steiner is a Principal of Origin Merchant Partners having over 20 years of experience as an investment banker, capital markets advisor, and CFO, working closely with healthcare and growth companies on successful financings and strategic transactions. Ms. Steiner was previously CFO for technology companies through capital raising and M&A transactions.

For over a decade prior to that, Ms. Steiner was Managing Director for Nucleus GC, a boutique healthcare advisory firm working with numerous clients on financings and strategic transactions, as well as product development, commercialization, positioning and launch. For nearly ten years prior to that, Ms. Steiner led Healthcare Investment Banking for CIBC World Markets and Yorkton Securities. Ms. Steiner has significant experience in dealings with public and private healthcare companies at all stages of development, and across all subsectors including pharmaceutical, medical device, healthcare information technology, drug development and healthcare services. Ms. Steiner holds a MBA from the Schulich School of Business at York University and a MSc in Immunology from McMaster University. She has a CPA, CA designation, earned while working at Deloitte, and contributes to her field as a volunteer advisor for the healthcare practice at MaRS Discovery District in Toronto and as an occasional lecturer for the Chartered Professional Accountants of Ontario.

Cary G. Vance

President and Chief Executive Officer

Mr. Vance was appointed President and CEO of Titan Medical in July 2022. Prior to being appointed, he served as an independent director for Titan Medical’s Board of Directors and as the company’s Human Resources/Compensation Committee Chair leading the company’s compensation policies and philosophical direction.
Previously, he served as President and CEO at Xcath Incorporated and drove strategic and tactical initiatives to advance the robotic platform enabling precise manipulation of robotically steerable guidewires for neurovascular and peripheral vascular clinical applications. Prior to Xcath, Mr. Vance led OptiScan Biomedical Corporation as President and CEO, leveraging a novel medical technology platform that continuously monitored systems in the surgical intensive care unit. Prior to this, Mr. Vance served as President and CEO at Myoscience Incorporated, and President and CEO of Hansen Medical Inc. While at 

Hansen Medical, he strategically transformed the business and markets with disruptive, enabling and game-changing interventional robotic techniques and technology. Mr. Vance drove adoption and record levels of year-over-year catheter utilization and system placements, while significantly reducing and reallocating spending levels. He later executed on an equity and debt financing strategy as an integral step to a successful M&A event. Prior to Hansen, Mr. Vance served in various global executive leadership roles over 20 years at Teleflex, Covidien and GE Healthcare. Mr. Vance currently serves on the AdvaMed Accel Board of Directors and is NACD Directorship Certified and is Lean/Six Sigma Black Belt Certified. Mr. Vance earned both a Bachelor of Arts degree in Economics and an MBA from Marquette University.